• MoA Technology

  Participated · Series C · Jul 2026

  Spun out of the University of Oxford in 2017, Moa Technology operates proprietary discovery platforms that have screened over 900,000 compounds and discovered more than 80 novel mode of action areas capable of breaking weed resistance. Several of its advanced programmes are now in their third year of international field trials, and in 2025 the company disclosed a new category of non-herbicidal products called Moa Amplifiers. Moa has established R&D collaborations with major industry partners including Nufarm, Gowan, Certis Belchim and Corteva Agriscience to progress commercial applications. The company plans to use its Series C proceeds and partner payments to push three lead programmes closer to commercialisation, expand its early-stage pipeline, and continue development of the Moa Amplifiers strategy. Its platform and commercial partnerships are positioned to support further industry deals and field deployment of its discoveries.

• Genomics

  Participated · Equity · Jan 2024

  Genomics develops precision healthcare tools using large-scale genetic data to generate personalised and population-level polygenic risk assessments. Its core product comprises proprietary algorithms and databases that link small genomic variations across thousands of studies to estimate individual risk for common diseases and cancers. The company positions its technology within genomic prevention to enable targeted interventions and tailored screening to prevent disease or catch it early. Genomics plans to use the new £35M funding to further develop its risk estimation technology and to expand its workforce as it aims to reach profitability. It has a team of over 100 people, more than 50% of whom are women with PhDs, and maintains offices in the UK and the US. The company expects adoption to scale over the next decade, forecasting that genetic information will become ubiquitous in healthcare systems and that millions in the UK will soon have personalised risk information based on its tools. Genomics plc is a data science company that uses human genetic information to improve drug development. Its core offering is an analysis engine that links genetic variation at over 14 million positions to changes in 7,000 molecular, cellular, and physiological measurements and disease outcomes, totaling over 100 billion data points. The company applies proprietary machine learning and statistical algorithms to predict the impact, efficacy, and safety of therapeutic interventions. Formed in 2014 by four University of Oxford scientists including Professors Peter Donnelly and Gil McVean, Genomics is based in Oxford, UK. It closed a £25m Series B led by Vertex Pharmaceuticals and plans to use the proceeds to expand, enhance its database, and pursue opportunities in the space. Genomics has also announced a collaboration with Vertex to further advance drug development efforts.

• Atom Bank

  Participated · Equity · Nov 2023

  Atom is a mobile, app-based bank that offers mortgages and savings via its app and provides secured business lending for small and medium-sized enterprises. The company offers customer support by phone, chat, email and social channels. Launched in 2016 and based in Durham, Atom recently reported its first full year of operating profit. FY23 results showed 62% revenue growth, customer numbers doubling to 224,000, and savings deposits rising to £6.6bn. The company says its current quarterly run-rate is generating +£100m of annualised net interest income and +£25m of operating profit. Since launch Atom has lent more than £4bn to UK homeowners and over £1bn to small businesses. Atom bank operates an app-based bank that offers mortgages and savings products through its mobile app, alongside secured business lending for small and medium-sized enterprises. The bank provides customer support via phone, chat, email and social channels. Launched in April 2016 and led by CEO Mark Mullen, Atom has grown to a team of over 470 people. The company is based in Durham and in 2022 signed a five-year Memorandum of Understanding with Durham University to progress research and diversity initiatives. Financially, Atom has been actively fundraising, having raised more than £100m over the last 12 months and using new proceeds to fund ongoing growth and development of the bank. Atom is a digital, app-based bank that launched operations in April 2016 and offers Fixed Saver accounts, an Instant Saver, secured business lending for SMEs and an automated mobile mortgage proposition. The company has a team of over 400 people and has continued to grow revenues while tightly controlling costs. Atom delivered its first monthly operating profit during Q2 and is pursuing a drive to IPO. Over the past 12 months the lender has raised more than £115m. The bank continues to expand its retail and SME products via its mobile-first platform. Atom Bank is a UK digital challenger bank launched in April 2016. It has loaned £2.8 billion to UK mortgage customers since launch and plans to grow lending to SMEs on its balance sheet to over £700 million by the end of March 2021. The bank is raising £40 million (about €46.4 million) from existing investors to support that growth. Existing investors named include BBVA, Toscafund, and Woodford Patient Capital Trust; Atom has raised about £450 million to date. CEO Mark Mullen said the capital raise will allow the company to continue to progress towards profitability and to improve efficiency and engagement. The firm is planning a public listing as early as next year and is targeting the 2022/23 financial year for an IPO. Atom Bank is a UK challenger bank focused on mobile-first savings accounts, residential mortgages and small-business lending, targeting mainly millennial customers. It has been migrating its core banking technology to Thought Machine’s Vault platform to move operations to the cloud and reduce running costs. The bank plans to expand its product range (including Instant Access savings in the autumn) and is hiring, with 50 new North East roles planned. Operational metrics show total lending up 76% year-over-year to £2.4 billion, with deposits of £1.8 billion (up from £1.4 billion). Atom reports weekly applications of up to £20 million for business loans and £10 million for residential mortgages. The company was co-founded by Anthony Thomson and positions itself to compete with other UK challenger banks.

No current team members are available.